Воспроизведено
-
Over the Past 2 seasons Bethany and Molly have discussed the lack of consistent, accessible treatment and the current ways we can treat an alloimmunized mom and her children with HDFN, but on this episode with Dr. Moise we discuss a bright future. Can a simple carbon monoxide reader replace a needle procedure to monitor for anemia? Can a drug stop antibodies from crossing the placenta entirely? We look to the cutting edge of medical treatment for disease that brought these women together.
Guest: Dr. Kenneth J Moise Jr, M.D. Dell Medical School – UT Austin
Director, Comprehensive Fetal Care Center Dell Children’s Medical CenterDONATE TO AHF AFRICA
Episode Topics:
Severity of subsequent alloimmunized pregnanciesIVIG and importance of timely treatmentIdeal newborn management of HDFNAntibody-specific differences in newborn HDFN presentationErythropoietin to prevent or delay need for neonatal transfusionCell free fetal DNA (cffDNA) (Billion To One’s Unity Screen) for fetal antigen typing instead of amniocentesisExhaled carbon monoxide to monitor for newborn anemiaNipocalimab trial updateState of alloimmunization/HDFN in AfricaWhat can you do to help?Links:
Leiden paper on disease severity in subsequent alloimmunized pregnanciesPETIT trial on IVIGLeiden paper on neonatal management of HDFNErythropoietin for newborns with HDFN to delay or reduce need for transfusioncffDNA for fetal antigen statusUtah study on carbon monoxide to detect hemolysisNipocalimab for HDFN:Clinical trial listing (continuously updated)Phase 2 resultsAHF/Dr. Moise live webinar with allo moms on nipocalimabEthiopia studyWorldwide Initiative for the Eradication of Rh DiseaseRhesus Solution Initiative (Nigeria)DONATE TO AHF AFRICAGeneral donation to AHFResearch for this episode provided by Bethany Weathersby and Molly Sherwood of the Allo Hope Foundation. Find more information at https://allohopefoundation.org
The Allo Podcast is produced and edited by Media Club.
